De, P;
Khine, MT;
Frankel, A;
Goldet, G;
Banerjee, D;
Montero, RM;
Chowdhury, TA;
Fogarty, D;
Karalliedde, J;
Mallik, R;
et al.
De, P; Khine, MT; Frankel, A; Goldet, G; Banerjee, D; Montero, RM; Chowdhury, TA; Fogarty, D; Karalliedde, J; Mallik, R; Patel, DC; Wahba, M; Winocour, P; Zac-Varghese, S; Bain, S; Sharif, A; Bellary, S; Dasgupta, I
(2025)
Finerenone in the management of diabetes kidney disease.
BMC Nephrol, 26 (1).
p. 63.
ISSN 1471-2369
https://doi.org/10.1186/s12882-025-03985-9
SGUL Authors: Banerjee, Debasish
|
PDF
Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview |
Abstract
People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and cardiovascular disease. Slowing progression of kidney disease and reducing cardiovascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD. However, emerging therapy such as non-steroidal selective mineralocorticoid antagonists (finerenone) is proven to lower blood pressure and further reduce the risk of progression of DKD and cardiovascular disease in people with type 2 diabetes. This consensus reviews current evidence and make recommendations for the use of finerenone in the management of diabetes kidney disease in the UK.
| Item Type: | Article |
|---|---|
| Additional Information: | © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| Keywords: | ACE inhibitors, Albuminuria, Angiotensin receptor blockers, Diabetes, Diabetic kidney disease, Finerenone, Hypertension, Renin Angiotensin Aldosterone System (RAAS), Humans, Naphthyridines, Diabetic Nephropathies, Mineralocorticoid Receptor Antagonists, Diabetes Mellitus, Type 2, Humans, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Naphthyridines, Mineralocorticoid Receptor Antagonists, 1103 Clinical Sciences, Urology & Nephrology |
| SGUL Research Institute / Research Centre: | Academic Structure > Institute of Medical, Biomedical and Allied Health Education (IMBE) |
| Journal or Publication Title: | BMC Nephrol |
| ISSN: | 1471-2369 |
| Language: | eng |
| Publisher License: | Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 |
| PubMed ID: | 39923037 |
 |
Go to PubMed abstract |
| URI: | https://openaccess.sgul.ac.uk/id/eprint/117173 |
| Publisher's version: | https://doi.org/10.1186/s12882-025-03985-9 |
Statistics
Actions (login required)
 |
Edit Item |